Companies › Bristol Myers Squibb · Global Markets & Policy
Bristol-Myers Squibb Company
- NYSE: BMY
US drugmaker focused on cancer, immunology, cardiovascular and neuroscience medicines.
Next earnings report: Oct 29, 2026. Bristol Myers Squibb quarterly results and earnings history →
Insider trades (Form 4)
Last 120 days: open-market sales $437K, purchases $0. All Bristol Myers Squibb insider transactions →
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Cristian Massacesi EVP,Chief Med Offr,Head of Dev | Open-market sale | 6,249 | $64.57 | $403K | Form 4 ↗ |
| Aug 25, 2026 | Phil M Holzer SVP and Controller | Open-market sale | 500 | $67.50 | $34K | Form 4 ↗ |
Key financials
| Metric | FY to Dec 2022 | FY to Dec 2023 | FY to Dec 2024 | FY to Dec 2025 |
|---|---|---|---|---|
| Revenue | $46.2B | $45.0B | $48.3B | $48.2B |
| Net income | $6.3B | $8.0B | −$8.9B | $7.1B |
| Diluted EPS | $2.95 | $3.86 | $-4.41 | $3.46 |
Fiscal years, from annual reports (10-K / 20-F). Source: SEC EDGAR (XBRL company facts), retrieved 2026-10-14. Verify figures against the original filings.
Recent filings
- 2026-07-30 · 10-Q
- 2026-07-30 · 8-K — Results of operations; Regulation FD disclosure
- 2026-05-08 · 8-K — Shareholder vote results
- 2026-04-30 · 10-Q
- 2026-04-30 · 8-K — Results of operations; Regulation FD disclosure
- 2026-03-25 · DEF 14A
- 2026-02-11 · 10-K
- 2026-02-05 · 8-K — Results of operations; Regulation FD disclosure
Source: SEC EDGAR, retrieved 2026-10-14. Filing types explained: 8-K, 10-Q, 10-K, 20-F / 6-K.
Not investment advice. This page lists official filings and our reports for reference. SignalStack does not rate securities or recommend buying or selling anything.